The aims of this study were to review and compare the use of systemic chemotherapy and EGFR–TKI and the clinical outcomes (OS, PFS, and complication rates) for elderly with advanced-stage NSCLC but no known EGFR mutation status. Here, EGFR is linked to non-small cell lung carcinoma.